CTLA4 and melanoma: The expert panel the results of the Phase II clinical trial of 227 patients with advanced melanoma treated with CTLA-4 inhibitor (Ipilimumab) agent and defined a new response assessment criteria, the irRC that they developed from WHO criteria [25].